Andrew Berens
Stock Analyst at Leerink Partners
(2.45)
# 2,503
Out of 5,113 analysts
98
Total ratings
53.01%
Success rate
-1.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Upgrades: Outperform | $8 | $3.95 | +102.53% | 1 | Jan 23, 2026 | |
| COGT Cogent Biosciences | Maintains: Outperform | $14 → $15 | $38.36 | -60.90% | 6 | Jun 13, 2022 | |
| GLTO Galecto | Initiates: Outperform | $46 | $24.45 | +88.14% | 1 | Jan 7, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $34 → $40 | $28.31 | +41.29% | 13 | Dec 26, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $140 → $149 | $100.27 | +48.60% | 3 | Nov 17, 2025 | |
| IMRX Immuneering | Initiates: Outperform | $15 | $5.00 | +200.00% | 1 | Oct 31, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $12.98 | +92.60% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $114.53 | -47.61% | 2 | Jul 28, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $12.93 | -30.39% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $6.16 | -2.60% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $880 → $762 | $751.13 | +1.45% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.83 | +1,066.08% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $22.31 | +12.06% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $139.72 | -31.29% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $101.18 | -22.91% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $17.87 | +56.69% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $93.22 | -15.25% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $2.56 | +954.69% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $11.85 | +110.97% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $5.42 | +638.01% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $2.03 | +3,200.49% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $21.13 | -5.35% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $11.18 | +123.61% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $10.28 | -22.18% | 7 | Jul 14, 2017 |
Relmada Therapeutics
Jan 23, 2026
Upgrades: Outperform
Price Target: $8
Current: $3.95
Upside: +102.53%
Cogent Biosciences
Jun 13, 2022
Maintains: Outperform
Price Target: $14 → $15
Current: $38.36
Upside: -60.90%
Galecto
Jan 7, 2026
Initiates: Outperform
Price Target: $46
Current: $24.45
Upside: +88.14%
Agios Pharmaceuticals
Dec 26, 2025
Maintains: Outperform
Price Target: $34 → $40
Current: $28.31
Upside: +41.29%
Nuvalent
Nov 17, 2025
Maintains: Outperform
Price Target: $140 → $149
Current: $100.27
Upside: +48.60%
Immuneering
Oct 31, 2025
Initiates: Outperform
Price Target: $15
Current: $5.00
Upside: +200.00%
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $12.98
Upside: +92.60%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $114.53
Upside: -47.61%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $12.93
Upside: -30.39%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $6.16
Upside: -2.60%
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $751.13
Upside: +1.45%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.83
Upside: +1,066.08%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $22.31
Upside: +12.06%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $139.72
Upside: -31.29%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $101.18
Upside: -22.91%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $17.87
Upside: +56.69%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $93.22
Upside: -15.25%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $2.56
Upside: +954.69%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $11.85
Upside: +110.97%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $5.42
Upside: +638.01%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.03
Upside: +3,200.49%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $21.13
Upside: -5.35%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $11.18
Upside: +123.61%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $10.28
Upside: -22.18%